News - Oncology, Halaven

Filter

Current filters:

OncologyHalaven

Popular Filters

Eisai’s breast cancer drug Halaven receives MAA in Europe

Eisai’s breast cancer drug Halaven receives MAA in Europe

03-07-2014

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Eisai ties up with Newbridge to market Halaven in Middle East

Eisai ties up with Newbridge to market Halaven in Middle East

18-11-2013

Japanese drug major Eisai says that its breast cancer drug Halaven (eribulin) will be marketed in selected…

EisaiHalavenMarkets & MarketingNewBridge PharmaceuticalsOncologyPharmaceuticalRest of the World

Eisai's new Belgium operation to help firm's globalization aims

16-09-2013

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

Breast cancer drug Halaven now available in Russia

12-09-2013

Japanese drug major Eisai (TYO: 4523) said this morning (September 12) that Halaven (eribulin) is now…

EisaiEuropeHalavenMarkets & MarketingOncologyPharmaceutical

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta

03-06-2013

Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Eisai files for new Halaven indication; gets orphan status for lenvatinib in EU

08-05-2013

Japanese drug major Eisai (TYO: 4523) has filed a Type II Variation application with the European Medicines…

EisaiEuropeHalavenlenvatinibOncologyPharmaceuticalRegulation

Eisai joins trend to enter Russian pharma market, with Halaven launch

26-03-2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai gets South Korean approval for breast cancer drug Halaven

04-09-2012

The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from…

Asia-PacificEisaiHalavenOncologyPharmaceuticalRegulation

Eisai enters deals with Valeant and Minophagen

04-04-2012

The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

17-11-2011

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Back to top